Volume | 716,449 |
|
|||||
News | - | ||||||
Day High | 17.64 | Low High |
|||||
Day Low | 16.74 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Acadia Realty Trust | AKR | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.60 | 16.74 | 17.64 | 16.92 | 17.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,876 | 716,449 | $ 16.98 | $ 12,163,996 | - | 12.37 - 17.90 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 91,970 | $ 16.92 | USD |
Acadia Realty Trust Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.74B | 102.58M | - | 338.69M | 19.87M | 0.19 | 87.35 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acadia Realty News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.36 | 17.90 | 16.74 | 17.31 | 899,226 | -0.44 | -2.53% |
1 Month | 16.64 | 17.90 | 16.375 | 17.09 | 1,167,853 | 0.28 | 1.68% |
3 Months | 17.16 | 17.90 | 16.095 | 16.75 | 1,155,524 | -0.24 | -1.40% |
6 Months | 15.26 | 17.90 | 14.06 | 16.65 | 1,039,214 | 1.66 | 10.88% |
1 Year | 13.41 | 17.90 | 12.37 | 15.69 | 918,945 | 3.51 | 26.17% |
3 Years | 21.17 | 23.33 | 12.28 | 17.12 | 733,117 | -4.25 | -20.08% |
5 Years | 28.83 | 29.5496 | 9.10 | 17.41 | 713,057 | -11.91 | -41.31% |
Acadia Realty Description
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |